Director of Operations Sean Wu presented a poster and gave a talk on sialoglycoconjugate detection and enrichment products. Learn more...
Lectenz Bio receives patent issuance from USPTO
The Lectenz Bio team is excited to announce the approval of its patent for the Lectenz® platform technology. This paves the way...
Lectenz Bio receives NIH SBIR Phase II
The National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further develop sialic...
Lectenz Bio receives NIH SBIR Phase I
The National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio a second SBIR Phase I to apply the...
Lectenz Bio receives NIH grants
Lectenz Bio receives a U01 from the NIH Common Fund Glycoscience program to further develop GlycoSenseTM technology. Lectenz Bio receives...
CSO Lori Yang @ San Diego Startup Week
Dr. Lori Yang, co-Founder and CSO of Lectenz Bio, will be a featured panelist at San Diego Startup Week on June 20th. Dr. Yang will share...
Three mutations switch H7N9 influenza to human-type receptor specificity
Prof. Robert J. Woods, President and co-Founder, and collaborators reported in PLoS Pathogens on Thursday, June 15th that three mutations...
Lectenz Bio receives patent issuance from USPTO
The Lectenz Bio team is excited to announce the approval of its first patent for a carbohydrate-like small molecule inhibitor. This...
CSO Lori Yang talks about her work on International Women’s Day
Lectenz Bio's Chief Scientific Officer and co-founder Lori Yang was recently interviewed by JLabs for her work on International Women's...